An indirect treatment comparison (ITC) and matching-adjusted indirect comparison (MAIC) between a 15-valent (V114) and a 20-valent (PCV20) pneumococcal conjugate vaccine among healthy infants

References

• Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004 Mar;4(3):144–154. doi: 10.1016/S1473-3099(04)00938-7
   PubMed Web of Science ®Google Scholar
• Nelson AL, Roche AM, Gould JM, et al. Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance. Infect Immun. 2007 Jan;75(1):83–90. doi: 10.1128/IAI.01475-06
   PubMed Web of Science ®Google Scholar
• Geno KA, Gilbert GL, Song JY, et al. Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev. 2015 Jul;28(3):871–899. doi: 10.1128/CMR.00024-15
   PubMed Web of Science ®Google Scholar
• Ganaie F, Saad JS, McGee L, et al. A New pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral Streptococcus. MBio. 2020 May 19;11(3). doi: 10.1128/mBio.00937-20
   Web of Science ®Google Scholar
• Westerink MA, Schroeder HW Jr., Nahm MH. Immune responses to pneumococcal vaccines in children and adults: rationale for age-specific vaccination. Aging Dis. 2012 Feb;3(1):51–67.
   PubMed Web of Science ®Google Scholar
• Berical AC, Harris D, Dela Cruz CS, et al. Pneumococcal vaccination strategies. An update and perspective. Ann Am Thorac Soc. 2016 Jun;13(6):933–944. doi: 10.1513/AnnalsATS.201511-778FR
   PubMed Web of Science ®Google Scholar
• Active Bacterial Core Surveillance (ABCs) report, emerging infections program network, Streptococcus pneumoniae, 2019. Atlanta (GA): Centers for Disease Control and Prevention; 2019 [cited 2023 May 16]. Available from: https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2019.pdf
   Google Scholar
• Simonsen L, Taylor RJ, Young-Xu Y, et al. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2011 Jan 25;2(1):e00309–10. doi: 10.1128/mBio.00309-10
   PubMed Web of Science ®Google Scholar
• Hu T, Song Y, Done N, et al. Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018. BMC Public Health. 2022 Sep 5;22(1):1677. doi: 10.1186/s12889-022-14051-6
   PubMed Web of Science ®Google Scholar
• Noharet-Koenig R, Lasota K, Faivre P, et al. Evolution of pneumococcal vaccine recommendations and criteria for decision making in 5 Western European Countries and the United States. MDM Policy Pract. 2023 Jan;8(1):23814683231174432. doi: 10.1177/23814683231174432
   Google Scholar
• Mungall BA, Hoet B, Nieto Guevara J, et al. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. Expert Rev Vaccines. 2022 Feb;21(2):201–214. doi: 10.1080/14760584.2022.2012455
   PubMed Web of Science ®Google Scholar
• Pettigrew MM, Alderson MR, Bakaletz LO, et al. Panel 6: vaccines. Otolaryngol Head Neck Surg. 2017 Apr;156(4_suppl):S76–s87. doi: 10.1177/0194599816632178
   PubMedGoogle Scholar
• McLaughlin JM, Utt EA, Hill NM, et al. A current and historical perspective on disparities in US childhood pneumococcal conjugate vaccine adherence and in rates of invasive pneumococcal disease: considerations for the routinely-recommended, pediatric PCV dosing schedule in the United States. Hum Vaccin Immunother. 2016;12(1):206–212. doi: 10.1080/21645515.2015.1069452
   PubMed Web of Science ®Google Scholar
• Adam HJ, Karlowsky JA, Baxter MR, et al. Analysis of MDR in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-2020. J Antimicrob Chemother. 2023 May 3;78(Supplement_1):i17–i25. doi: 10.1093/jac/dkad066
   PubMedGoogle Scholar
• VAXNEUVANCE Prescribing Information. United States Food and Drug Administration; 2022 [cited 2023 May 16]. Available from: https://www.fda.gov/media/150819/download
   Google Scholar
• PREVNAR. 20 prescribing information. United States Food and Drug Administration 2023. Available from: https://www.fda.gov/media/149987/download
   Google Scholar
• Lupinacci R, Rupp R, Wittawatmongkol O, et al. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED). Vaccine. 2023 Jan 27;41(5):1142–1152. doi: 10.1016/j.vaccine.2022.12.054
   PubMedGoogle Scholar
• Watson W 20-valent pneumococcal conjugate vaccine (PCV20) phase 3 in pediatrics. ACIP. 2023. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-22/Pneumococcal-04-Watson-508.pdf
   Google Scholar
• Clinical trial results: a phase 3, multicenter, randomized, Double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114 in healthy infants (PNEU-PED). EU Clinical Trials Register. 2022 [cited 2023 May 15]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004109-21/results
   Google Scholar
• Merck Sharp & Dohme LLC. NCT03893448: safety, tolerability, and immunogenicity of V114 in healthy infants (V114-029) (PNEU-PED). ClinicalTrials.Gov 2019 [cited 2023 May 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT03893448
   Google Scholar
• Pfizer. NCT04382326: 20-valent pneumococcal conjugate vaccine safety and immunogenicity study of a 4-dose series in healthy infants. ClinicalTrials.Gov 2020 [cited 2023 May 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT04382326
   Google Scholar
• Clinical trial results: a phase 3, randomized, Double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy infants. EU Clinical Trials Register 2023 [cited 2023 May 15]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003305-10/results
   Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997 Jun;50(6):683–691. doi: 10.1016/S0895-4356(97)00049-8
   PubMed Web of Science ®Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in Health technology appraisal. Med Decis Making. 2018 Feb;38(2):200–211. doi: 10.1177/0272989X17725740
   PubMed Web of Science ®Google Scholar
• Mt-Isa S, Abderhalden LA, Musey L, et al. Matching-adjusted indirect comparison of pneumococcal vaccines V114 and PCV20. Expert Rev Vaccines. 2022 Jan;21(1):115–123. doi: 10.1080/14760584.2021.1994858
   PubMed Web of Science ®Google Scholar
• Park DE, Johnson TS, Nonyane BA, et al. The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity. Pediatr Infect Dis J. 2014 Jan;33(Suppl 2):S130–9. Suppl 2 Optimum Dosing of Pneumococcal Conjugate Vaccine For Infants 0 A Landscape Analysis of Evidence Supportin g Different Schedules. doi: 10.1097/INF.0000000000000081
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Moisi J, Moulton LH, et al. Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial. J Infect Dis. 2007 Jul 1;196(1):104–114. doi: 10.1086/518438
   PubMed Web of Science ®Google Scholar
• Nieminen H, Rinta-Kokko H, Jokinen J, et al. Effectiveness of the 10-valent pneumococcal conjugate vaccine among girls, boys, preterm and low-birth-weight infants - results from a randomized, double-blind vaccine trial. Vaccine. 2019 Jun 19;37(28):3715–3721. doi: 10.1016/j.vaccine.2019.05.033
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012 Sep;15(6):940–947. doi: 10.1016/j.jval.2012.05.004
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. PharmacoEconomics. 2010;28(10):935–945. doi: 10.2165/11538370-000000000-00000
   PubMed Web of Science ®Google Scholar
• Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985 Apr;4(2):213–226. doi: 10.1002/sim.4780040211
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014 Sep;14(9):839–846. doi: 10.1016/S1473-3099(14)70822-9
   PubMed Web of Science ®Google Scholar
• WHO. Annex 3 recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines. 2013 [cited 2023 Jul 19]. Available from: https://cdn.who.int/media/docs/default-source/biologicals/vaccine-standardization/pneumococcus/trs_977_annex_3.pdf
   Google Scholar
• Jódar L, Butler J, Carlone G, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine. 2003 Jul 4;21(23): 3265–72.
   PubMed Web of Science ®Google Scholar
• Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007 May 10;25(19): 3816–26.
   PubMed Web of Science ®Google Scholar
• Ryman J, Weaver J, Hu T, et al. Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data. NPJ Vaccines. 2022 Nov 7;7(1): 140.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Annex 3: recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines. WHO expert committee on biological standardization, sixtieth report. Geneva (Switzerland): World Health Organization (WHO); 2013. p. 91–151
   Google Scholar
• Dagan R, Givon-Lavi N, Fraser D, et al. Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis. 2005 Aug 1;192(3): 367–76.
   PubMed Web of Science ®Google Scholar
• Dagan R, Juergens C, Trammel J, et al. Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration. Vaccine. 2016 Aug 5;34(36): 4313–20.
   PubMed Web of Science ®Google Scholar
• Voysey M, Fanshawe TR, Kelly DF, et al. Serotype-specific correlates of protection for pneumococcal carriage: an analysis of immunity in 19 countries. Clin Infect Dis. 2018 Mar 5;66(6):913–920.
   PubMed Web of Science ®Google Scholar
• Tan CY, Immermann FW, Sebastian S, et al. Evaluation of a validated Luminex-based multiplex immunoassay for measuring immunoglobulin g antibodies in serum to pneumococcal capsular polysaccharides. mSphere. 2018 Aug 8;3(4):10–128.
   Web of Science ®Google Scholar